Table 1.

Patient characteristics and the effect of aspirin on all-cause mortality and cancer mortality in randomized trials of aspirin (with an initial treatment period ≥ 4 years) (Peto et al, 1988; Farrell et al, 1991; ETDRS Investigators, 1992; Juul-Möller et al, 1992; Thrombosis Prevention Trial, 1998; Ogawa et al, 2008; Belch et al, 2008; Fowkes et al, 2010; Rothwell et al, 2011).

	TPT	UK-TIA	BDT	ETDRS	JPAD	SAPAT	POPADAD	AAAT
Placebo-controlled, double-blind	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes
Patients (n)	5,085	2,435	5,139	3,711	2,539	2,035	1,276	3,350
Median duration of scheduled treatment (years)	6.9	4.4	6.0	5.0	4.4	4.2	6.7	8.2
Aspirin dose (mg/day)	75	300/1,200	500	650	81/100	75	100	100
Odds ratio (95% CI) for any cancer death	0.83 (0.62–1.11)	0.45 (0.25–0.82)	0.79 (0.55–1.14)	1.14 (0.56–2.35)	0.80 (0.47–1.37)	0.53 (0.25–1.15)	0.80 (0.47–1.37)	0.86 (0.63–1.17)
Odds ratio (95% CI) for any death	1.06 (0.87–1.29)	0.90 (0.70–1.14)	0.88 (0.72–1.09)	0.91 (0.77–1.08)	0.88 (0.55–1.40)	0.77 (0.57–1.04)	0.92 (0.68–1.25)	0.94 (0.76–1.17)

AAAT, Aspirin for Asymptomatic Atherosclerosis Trial; BDT, British Doctor’s Trial; ETDRS, Early Treatment Diabetic Retinopathy Study; JPAD, Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes; POPADAD, Prevention of Progression of Arterial Disease and Diabetes; SAPAT, Swedish Angina Pectoris Aspirin Trial; TPT, Thrombosis Prevention Trial; UK-TIA, UK-Transient Ischaemic Attack; CI, confidence interval.